Cardiovascular effects of valdecoxib: Transducing human pharmacology results into clinical read-outs

Expert Opinion on Drug Safety

Volumn 7, Issue 1, 2008, Pages 29-42

  Capone, Marta L ^a   Tacconelli, Stefania ^a   Di Francesco, Luigia ^a   Petrelli, Maria ^a   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Aspirin; Cardiovascular toxicity; COX 2; Coxibs; NSAIDS; Parecoxib; Prostacylin; Thromboxane; Valdecoxib

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DEXTROMETHORPHAN; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETORICOXIB; FLECAINIDE; FLUCONAZOLE; FLURBIPROFEN; IBUPROFEN; KETOCONAZOLE; KETOPROFEN; LOOP DIURETIC AGENT; LUMIRACOXIB; MELOXICAM; METOPROLOL; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PHENYTOIN; PLACEBO; PROPAFENONE; ROFECOXIB; UNINDEXED DRUG; VALDECOXIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CORONARY ARTERY BYPASS GRAFT; DEEP VEIN THROMBOSIS; DRUG ANTAGONISM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; EDEMA; ENZYME INHIBITION; EPIDERMOLYSIS; ERYTHEMA MULTIFORME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; OSTEOARTHRITIS; POSTOPERATIVE PAIN; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; SODIUM RETENTION; STEVENS JOHNSON SYNDROME; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOSIS; VASCULAR DISEASE; WOUND INFECTION;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOXAZOLES; SULFONAMIDES;

EID: 38949197394     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.1.29     Document Type: Review

References (96)

1. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345(6):433-42
2. Grosser T, Fries S, Fitzgerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116(1):4-15
3. Kearney PM, Baigent C, Godwin J, Halls H, Emberaon JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332(7553):1302-8
4. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98(3):266-74
5. Rodríguez LA, Patrignani P. The ever growing stony of cyclo-oxygenase inhibition. Lancet 2006;368:1745-7
6. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007;82(1-4):85-94
7. Brooks P, Emery P, Evans JF, et al. Interpreting the dinkal significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford) 1999;38(8):779-88
8. Meade EA, Smith WL, Dewitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs. J Biol Chem 1993;268:6610-14
9. Laneuville O, Breuer DK, Dewitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthase-1 and -2 by nonsteroidal antiinflammatoty drugs. J Pharmacol Exp Ther 1994;271:927-34
10. Walker MC, Kurumbail RG, Kiefer JR, et al. A three-step kinetic mechanism for selective inhibition of cyclooxygenase-2 by diarylheterocyclic inhibitors. Biochem J 2001;357:709-18
11. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of non-steroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-7
12. Swinney DC, Mak AY, Barnett J, Ramesha CS. Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. J Biol Chem 1997;272(19):12393-8
13. Lazo JS, Parker KL. Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 11th Edition. LL. Brunton, 2005
14. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271(3):1705-12
15. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17(3-4):317-27
16. Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999;50(4):661-7
17. Cryer B, Feldman M. Cyclooxygenase-1 and cylooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-21
18. Huntjens DR, Danhof M, Della Pasqua OE. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) 2005;44(7):846-59
19. Patrignani P, Panara MR, Sciulli MG, Santuni G, Renda G, Patrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal and-inflammatory drugs. J Physiol Pharmacol 1997;48:623-31
20. Tacconelli S, Capone ML, Sciulli MG, Ricciotti E, Patrignani P. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Ret Opin 2002;18(8):503-11
21. Patrignani P, Campestrini J, Branson J, et al. Lumiracoxib is a selective inhibitor of cyclooxygenase-2 in patients with osteoarthritis. Ann Rheum Dis 2004;63:368
22. Topper JN, Cai J, Falb D, Gimbrone MA. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996;93:10417-22
23. Barry OP, Pratico D, Lawson JA, Fitzgerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997;99(9):2118-27
24. Caughey GE, Cleland LG, Gamble JR, James MJ. Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. J Biol Chem 2001;276(41):37839-45
25. Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980;66(5):979-86
26. Stitham J, Arehart EJ, Gleim SR, Douville KL, Hwa J. Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins & Other Lipid Mediators John C McGiff: Four decades of contributions to the study of eicosanoid-mediated regulation of vascular and renal function 2007;82:95-108
27. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-226
28. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-5
29. Rabausch K, Bretschneider B, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 2005;96:E1-E6
30. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539-41
31. Muratat, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997;388:678-82
32. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection an female mice. Science 2004;6:1954-7
33. Francois H, Athirakul K, Howell D, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2005;2(3):201-7
34. Mcadam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-7
35. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-41
36. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355(9):885-95
37. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355(9):873-84
38. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006114(10):1028-35
39. Majerus PW. Arachidonate metabolism in vascular disorders. J Clin Invest 1983;72(5):1521-5.
40. Raychowdhury MK, Yukawa M, Collins LJ, McGrail SH, Kent KC, Ware JA. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 1994;269(30):19256-61
41. Hirata M, Hayashi Y, Ushikubi F, et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991;349(6310):617-20
42. Habib A, Fitzgerald GA, Madouf J. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem 1999;274(5):2645-51
43. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353(22):2373-83
44. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69(6):1366-72
45. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004; 109(12):1468-71
46. Capone ML, Tacconel]i S, Sciulli MG, et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 2007;322(2):453-60
47. Reilly IA, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69(1):180-6
48. Sciulli MG, Renda G, Capone ML, et al. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. Clin Pharmacol Ther 2006;80(2):115-25
49. Minuz P, Gaino S, Zuliani V, et al. Functional role of p38 mitogen activated protein kinase in platelet activation induced by a thromboxane A2 analogue and by 8-iso-prostaglandin F2alpha. Thromb Haemost 2002;87(5):888-98
50. Sciulli MG, Capone ML, Tacconelli S, Patrignani P. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. Pharmacol Rep 2005;57:66-85
51. Qi Z, Hao C-M, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensun II. J Clin Invest 2002;110:61-9
52. Gurwitz JH, Avon J, Balm L, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994;272(10):781-6
53. Johnson AG, Nguyen TY, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300
54. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153(4):477-84
55. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13(4 Pt 1):418-26
56. Athirakul K, Kim HS, Audoly LP, Smithies O, Coffman TM. Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. Kidney Int 2001;60(6):2324-49
57. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165(5):490-6
58. Cannon CP, Curtis SR, Fitzgerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368(9549):1771-81
59. Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000;43(5):775-7
60. Fenton C, Keating GM, Wagstaff AJ. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain. Drugs 2004;64(11):1231-61
61. Talley JJ, Bertenshaw SR, Brown DL, et al. N- (5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 2000;43(9):1661-3
62. Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999;21(12):2065-79
63. Decision Memo - Analysis and Recommendations for Agency Action - COX-2 Selective and Non-selective NSAIDs. Available at: URL: www.fda.gov/cder/ drug/infopage/COX2/NSAIDdecisionMemo.pdf [last accessed December 2007]
64. HSA Drug Safety Information (no. 11) - Pfizer's voluntary suspension of sales of valdecoxib (Bextra®). Available at: URL:www.hsa.gov.sg/docs/ valdecoxib_8Apr2005.pdf [last accessed December 2007]
65. EMEA Public Statement on Valdecoxib (Bextra/Valdyn) and Parecoxib Sodium (Dynastat/Rayzon). Available at URL: www.emea.europa.eu/pdfs/human/press/ pus/20480204en.pdf [last accessed December 2007)
66. Tacconelli S, Capone ML, Patrignani P. Clinical pharmacology of novel selective COX-2 inhibitors. Curr Pharm Des 2004;10(6):589-601
67. Capone ML, Tacconelli S, Sciulli MG, Patrignani P. Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 2003;16:49-58
68. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000;38(3):225-42
69. VIOXX® (rofecoxib tablets and oral suspension) label information. Available at: URL:www.fda.gov/Cder/foi/label/l999/2lO42lbl.pdf [last accessed December 2007]
70. Agrawal NG, Porras AG, Matthews CZ, et al. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003;43(3):268-76
71. Karim A, Laurent A, Slater ME, et al. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol 2001;41(10):1111-19
72. Krishnaswami S. Pharmacokinetic profile of parecoxib sodium, an injectable prodrug of the COX-2 selective inhibitor, valdecoxib. Clin Pharmacol Ther 2002:P48.
73. Gierse JK, Zhang Y, Hood WF, et al. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther 2005;312(3):1122-206
74. Hinz B, Dormann H, Brune K. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 2006;54(1):282-91
75. Renda G, Tacconelli S, Capote ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with asteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006;80(3):264-74
76. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125(6):1481-92
77. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352(11):1081-91
78. Mangano DT; Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery N Engl J Med 2002;347(17):1309-17
79. Wan S, Leclerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997;112:676-92
80. Davies GC, Sobel M, Salzman EW. Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass. Circulation 1980;61:808-14
81. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1999;68:1905-12
82. Faymonvilie ME, Deby-Dupont G, Larbuisson R, et al. Prostaglandin E2, prostacyclin, and thromboxane changes during nonpulsatile cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 1986;91:858-66
83. Watkins WD, Peterson MB, Kong DL, et al. Thromboxane and prostacyclin changes during cardiopulmonary bypass with and without pulsatile flow. J Thorac Cardiovasc Surg 1982;84:250-6
84. Zimmermann N, Kienzle P, Weber AA, et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001;121(5):982-4.
85. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003;108(5):542-7.
86. Dixon DA, Tolley ND, Bemis-Standoli K, et al. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J Clin Invest 2006;116(10):2727-38
87. Evangelista V, Manarini S, Di Santo A, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006;98(5):593-5
88. Kato R, Foex P. Myocardial protection by anesthetic agents against ischemia-reperfusion injury an update for anesthesiologists. Can J Anaesth 2002;49(8):777-91
89. Tanaka K, Ludwig LM, Krolikowski JG, et al. Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. Anesthesiology 2004;100(3):525-31
90. Futagam A, Ishizaki M, Fukuda Y, et al. Wound healing involves induction of cyclooxygenase-2 expression in rat skin. Lab Invest 2002;82:1503-13
91. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 11th Edition. 2005. p. 653-70
92. Furberg CD, Psaty BM, Fitzgerald GA. Parecoxib, valdecoxib, and cardiovascular risk Circulation 2005;111(3):249.
93. http//www.fda.gov/medwatch/SAFETY/2004/apr_PI/Bextra_PI.pdf
94. Chen LC, Ashcroft DM. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf. 2007;16(7):762-72
95. Zaugg M, Lucchinetti E, Garcia C, Pasch T, Spahn DR, Schaul, MC. Anaesthetics and cardiac preconditioning. Part II. Clinical implications. Br J Anaesth 2003;91(4):566-76.
96. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-42